Effect of angiotensin II receptor blockers on efficacy and safety of Camrelizumab plus chemotherapy in the first-line therapy for advanced non-small cell lung cancer (ARMOR I): a protocol for a prospective, real-world, multicenter, intervention clini
The interplay between collagens, ARB, and cancer is still complex and worth further study. ARMOR I will provide crucial preliminary data on ARB's role in first-line therapy for advanced NSCLC. The potential application of ARB in other tumor types may also become an important area to explore.
Authors
- Jie Mei (ORCID: https://orcid.org/0000-0001-7799-8129)
- Yichao Zhu (ORCID: https://orcid.org/0000-0003-3499-8510)
- Yuhan Zhang (ORCID: https://orcid.org/0000-0002-8511-4562)
- Yun Cai (ORCID: https://orcid.org/0009-0005-0693-153X)
- Huning Jiang
- Hong Fan (ORCID: https://orcid.org/0000-0002-2005-1150)
- Zeyu Wang (ORCID: https://orcid.org/0000-0003-2670-4789)
- Huiyu Wang (ORCID: https://orcid.org/0000-0003-4984-6616)
- Rui Hou (ORCID: https://orcid.org/0000-0002-6950-2290)
- Junying Xu (ORCID: https://orcid.org/0009-0003-2242-5448)
Institutions
- Jiangsu University (CN)
- Jintan People's Hospital (CN)
- Wuxi People's Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-11
- DOI
- https://doi.org/10.3389/fimmu.2025.1668782
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Wuxi Municipal Bureau on Science and Technology